WTO Least-Developed Countries Request Waiver Of IP Rights On Pharma Products

Source: IP Watch

3 Sep 2015

This week at the World Trade Organization intellectual property committee meeting, least-developed countries submitted a request to extend a waiver allowing them not to enforce intellectual property rights on pharmaceutical products. The countries have extended the waiver before, but this time they are seeking to make it indefinite, until they are no longer considered LDCs.

Continue reading

Posted in LDC Extension, TRIPS plus | Leave a comment

Pharmaceutical firms spend €40m a year for ‘privileged access’ to EU decision-makers

Source: Independent

2 Sep 2015

Pharmaceutical companies spend tens of millions of euros on lobbyists every year to ensure “privileged access” to decision-makers in Brussels, according to a major new report that lifts the lid on their influence on EU drugs and healthcare policy.

The industry now spends at least €40m annually – 15 times more than NGOs and consumer groups, according to estimates – as representatives from “big pharma” enjoy a “staggering” number of meetings with European Commission departments and officials.

Continue reading

Posted in Regional Comprehensive Economic Partnership, TRIPS plus | Leave a comment

As TPP Grinds To A Halt, Asian Countries Start Focusing On Rival Trade Agreement RCEP

Source: Techdirt

2 Sep 2015

from the more-important-in-the-short-term dept

Recently, Techdirt has written dozens of stories about the Trans-Pacific Partnership agreement (TPP). That’s largely because it seemed to be coming to a conclusion, after many years of negotiations, and so it was important to capture the last-minute twists and turns — and the dirty deals — as they happened. But as we reported a few weeks ago, that final breakthrough and completion never happened. Instead, we had the “Maui meltdown”, when a whole bunch of old and new problems raised their heads, with the result that TPP may have missed a key deadline that means it won’t be happening soon, if ever. That may have seemed an extravagant claim, but it is a sentiment that is gradually beginning to spread among commentators in Asia. Here, for example, is The Diplomat, a specialist title covering that part of the world:

The Trans-Pacific Partnership is in trouble. Trade ministers failed last month to conclude the massive 12-nation trade deal by their hoped-for summer deadline, putting negotiations in danger of collapse.

Continue reading

Posted in Regional Comprehensive Economic Partnership, TRIPS plus | Leave a comment

Delhi HC issues notice on Prof. Shamnad Basheer’s PIL on patent working norms

Source: Live Law

2 Sep 2015

A Delhi High Court Bench comprising Chief Justice G. Rohini and Justice Jayant Nath hasreportedly sought a reply from the Government on Prof. Shamnad Basheer’s PIL regarding patent working norms.

The Government had been ordered to file its reply within 4 weeks. The matter is not posted to November 17. Prof. Basheer was represented by his counsels, Abhimanyu Bhandari and Sai Vinod.

Continue reading

Posted in Compulsory Licensing, Indian Patent Law, patent revocation, patent working | Leave a comment

HC notice to govt over MNCs’ patent disclosure

Source: Times of India

2 Sep 2015

MUMBAI: In a development that could have major ramifications on intellectual property cases in pharmaceutical and technology sectors, the Delhi high court issued a notice to the government on Tuesday in a PIL (public interest litigation) filed by IP expert Shamnad Basheer.

The petition exposes the weak enforcement of an important statutory provision, Form 27, which discloses patent data of a company. It says pharma and technology MNCs are not complying with this law, and are using it to block the entry of affordable versions in the market.

Continue reading

Posted in access to medicines, Compulsory Licensing, Indian Patent Law, patent revocation, patent working | Leave a comment

Classic case of misplaced ‘bravado’

Source: Business Line

24 Aug 2015

GVK’s tangle with the EU authorities is a regulatory issue, and not a trade concern

On May 22, 2015, the European Medicines Agency (EMA) reaffirmed its recommendation to suspend a number of medicines for which bioequivalence studies were done by GVK Biosciences in Hyderabad, on behalf of several marketing authorization holders in the European Union. This was on the basis of a re-examination requested by the affected parties. And the suspension is for two years.

Continue reading

Posted in Compulsory Licensing, EU-India FTA, TRIPS plus | Leave a comment

RCEP agreement: Ministers of 16 nations to finalise modalities on August 24 in Malaysia

Source: Economic Times

18 Aug 2015

NEW DELHI: As negotiations for Regional Comprehensive Economic Partnership(RCEP) agreement progress, ministers of 16 member countries, including India and China will meet in Kuala Lumpur on August 24 to finalise the modalities of the pact.

“The talks are progressing very well. The 9th round of talks for RCEP agreement was recently concluded in Myanmar. Now in the next ministerial level meeting, the modalities would be finalised,” a senior government official told PTI.

Continue reading

Posted in Regional Comprehensive Economic Partnership | Leave a comment